Mauna Kea (ENT:MKEA) said yesterday that it expanded a deal with Fujifilm Holdings (TSE:4901) to commercialize its Cellvizio laser endomicroscope in China.
The deal calls for Japan’s Fujifilm to commercialize Cellvzio for gastroenterological and pulmonary applications in the People’s Republic, and integrate the device into its own endoscopes.
Cellvizio 1st won approval from Chinese regulators in late 2012.
“This expanded commercial partnership with Fujifilm in China is fully in line with our new commercialization strategy that aims at integrating Cellvizio into leading interventional platforms,” founder & CEO Sacha Loiseau said in prepared remarks. “With our recent agreement with Cook Medical for urologic applications, we continue to further expand our strategic partnerships for a wide range of therapeutic applications for our unique endomicroscopy platform. We now have 2 solid partners to develop the important Chinese market.”
Cellvizio won 510(k) clearance from the FDA in October of last year, with Loiseau openly seeking help from some of the biggest names in medtech in commercializing the device.
The post Mauna Kea expands Fujifilm deal in China appeared first on MassDevice.
from MassDevice http://ift.tt/1P3Y8zt
Cap comentari:
Publica un comentari a l'entrada